Company intelligence / Profile preview
Thera-I
Seoul, Seoul, South Koreathera-i.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Thera-i is a South Korean biotechnology company specializing in the development of next-generation radiopharmaceuticals for cancer treatment and diagnosis. The company utilizes a theranostic approach, combining targeted therapy with molecular imaging to provide personalized medicine solutions. Their core focus is on targeted alpha therapy (TAT) and developing novel ligands for various oncology targets, including PSMA for prostate cancer. Thera-i aims to overcome the limitations of current radioligand therapies by improving targeting efficiency and reducing off-target toxicity through optimized ligand design.
- Therapeutic areas
- Oncology
- Modalities
- RadiopharmaceuticalBiologicSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Seoul National University Hospital
Beyond the preview
Go deeper on Thera-I.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thera-I.